Drugs / Fortesta
last change Jul 2023 re-read 2 minutes ago

Fortesta

Developed for
hypogonadism, male · hypogonadotropic hypogonadism

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) FORTESTA 2010-12-29 fda.gov

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04456296 Comparator Jun 2020 → Jul 2023 hypogonadism, male, hypogonadotropic hypogonadism Endo USA Inc., a Keenova Therapeutics Company Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Fortesta ClinicalTrials.gov intervention name — accepted as the source's own label NCT04456296